# Immunohematology Market > Immunohematology Market Research Report: Information by Product (reagents, instruments / analyzers, and consumables & accessories), By Application (blood related disorders and HIV), By End User (hospitals, diagnostic laboratories, and blood banks), By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.3% - **2024:** $ 1,761.26 Million - **2035:** $ 2,711.24 Million - **Key Players:** Companies such as Thermo Fisher Scientific Inc., Abbott, Merck KGaA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Grifols, S.A., Bio-Rad Laboratories, Danaher Corporation, Cardinal Health. are some of the major participants in the market. **Report ID:** MRFR/MED/41118-CR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 25, 2026 **URL:** https://www.marketresearchfuture.com/reports/immunohematology-market-42784 --- ## Market Summary ## **Immunohematology Market Overview** As per MRFR analysis, the Immunohematology Market Size was estimated at 3.19 (USD Billion) in 2023. The Immunohematology Market Industry is expected to grow from 3.36 (USD Billion) in 2024 to 5.9 (USD Billion) by 2035. The Immunohematology Market CAGR (growth rate) is expected to be around 5.25% during the forecast period (2025 - 2035). ### **Key Immunohematology Market Trends Highlighted** The Global Immunohematology Market is experiencing significant growth driven by several key factors. The increasing prevalence of blood disorders and the rising need for transfusion services are major drivers for market expansion. Additionally, the growing aging population and advancements in technology are leading to improved diagnostic and therapeutic options. There is a heightened awareness of safe blood transfusion practices, encouraging more hospitals and healthcare facilities to adopt advanced immunohematology products. The rise in regulations surrounding blood safety further emphasizes the importance of effective immunohematology testing and product development. Opportunities in the Global Immunohematology Market are vast, particularly with the ongoing research aimed at developing more efficient, user-friendly devices and reagents. The increasing demand for personalized medicine is also paving the way for tailor-made testing procedures, which can enhance patient outcomes. Moreover, expanding healthcare infrastructure in emerging markets offers a distinct opportunity for companies to introduce innovative products. Partnerships with blood banks and healthcare providers can also lead to the establishment of integrated solutions, optimizing the overall efficiency of blood transfusion services. In recent times, the market has seen trends focusing on automation and digitalization, enhancing the accuracy and speed of blood type testing and compatibility assessments. The shift toward remote and point-of-care testing has gained momentum, allowing for quicker decision-making and improved patient care. Furthermore, the use of artificial intelligence in immunohematology is providing new insights and predictive analytics that can streamline operations. Overall, the blending of technology with traditional practices is creating a dynamic landscape for the future of this market, setting a foundation for further growth and innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Immunohematology Market Drivers** ### Increasing Prevalence of Blood Disorders There has been an increase in supply and demand in the market of Global Immunohematology due to the greater prevalence of blood-related medical conditions such as sickle cell anemia, thalassemia, and hemophilia. With these changes in global health systems, there has been a greater need for effective strategies for blood typing and cross-matching. This increase in demand stems from the effort to develop new technologies that can boost the efficacy of labs as well as improve health outcomes for patients. Healthcare organizations around the world are investing in R&D to improve the understanding of blood-related medical diseases and conditions, which is meant is aiding the growth of the Global Immunohemathology Market. The advancement of diagnostic technologies alongside the increase in life expectancy has meant that blood-related medical conditions are on the rise which is why healthcare providers are relying heavily on immunohematology due to its promises as a safe method for patient management alongside blood transfusions. With all these factors considered, the market is shifting in the direction of greater importance towards blood safety and compatibility. Furthermore, with enhanced international regulations regarding the safety of blood, effective immunohematology solutions have become very important as well. With this in mind, blood-related disorders have an impact on the world market for immunohematology. ### Technological Advancements in Immunohematology Devices Technological advancements play a pivotal role in the growth of the Global Immunohematology Market Industry. Innovations such as automated blood analyzers and advanced molecular diagnostics have significantly enhanced the accuracy and efficiency of immunohematology processes. These next-generation devices not only reduce human error but also improve turnaround times for testing, which is vital in emergency healthcare settings. Moreover, the integration of artificial intelligence and machine learning in immunohematology testing is transforming the landscape, providing more robust data analytics and predictive modeling capabilities.As healthcare centers increasingly adopt these sophisticated technologies, they are positively influencing overall efficiency and patient care, thereby driving the demand for immunohematology services. ### Rising Demand for Blood Transfusion Services The Global Immunohematology Market Industry is significantly driven by the rising demand for blood transfusion services. As healthcare needs continue to expand globally, the reliance on safe and effective transfusion practices has increased, which directly correlates with the growth of immunohematology testing. Factors such as an increase in surgical procedures, trauma cases, and the need for treatment of chronic diseases require comprehensive blood transfusion services.This surge is further amplified by a growing number of emergency care cases requiring immediate blood supply, necessitating precise immunohematology testing. Improved awareness about blood-related diseases and the importance of blood component therapies is also propelling the demand for quality immunohematology solutions. ## **Immunohematology Market Segment Insights**  ### **Immunohematology Market Product Type Insights** The Global Immunohematology Market is delineated into various product types, prominently featuring Reagents, Instruments, and Software. In 2024, the total market is expected to be valued at approximately 3.36 USD Billion, with Reagents holding a majority position in this landscape, valued at 1.68 USD Billion, representing a significant share of the market. The vital role of Reagents in immunohematology cannot be overstated, as they are essential for blood typing, compatibility testing, and screening for antibodies, thereby directly impacting patient safety and transfusion practices.Instruments, which are valued at 1.2 USD Billion in 2024, follow as a crucial category, encompassing sophisticated technologies needed for executing immunohematology tests, including automated analyzers that enhance efficiency and accuracy in labs. With an increased push towards automation and precision medicine, the demand for these Instruments is expected to escalate, contributing significantly to the market's growth trajectory. Meanwhile, the Software segment, valued at 0.48 USD Billion in 2024, supports operations by streamlining data management and improving workflow efficiency. Although it represents the smallest segment currently, its importance is growing as healthcare facilities adopt advanced informatics systems for better patient management and regulatory compliance. Collectively, the Global Immunohematology Market data reflects a robust growth continuum from 2024 to 2035, with Reagents expected to expand to 3.02 USD Billion and Instruments to 1.89 USD Billion, signifying their dominant presence, while Software is projected to grow to 0.99 USD Billion in the same timeframe. This segmentation underscores the increasing emphasis on technological advancement and quality assurance in blood transfusion practices. The growth drivers include rising incidences of blood disorders and an increasing patient population requiring transfusions, while challenges such as regulatory hurdles and the necessity for skilled personnel do exist. However, there are ample opportunities for market expansion, particularly in the development of innovative reagents and advanced instruments, highlighting the dynamic nature of the Global Immunohematology Market industry. As a whole, the statistics surrounding the Global Immunohematology Market segmentation indicate a strategic focus on enhancing testing capabilities and patient care through continued investment in these essential product types, ensuring efficient and safe blood transfusion processes across healthcare systems globally.  Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Immunohematology Market Application Insights** The Global Immunohematology Market is poised for substantial growth, with a projected value of 3.36 USD Billion in 2024 and 5.9 USD Billion by 2035, reflecting an encouraging trend. The Application segment plays a critical role in this market, encompassing areas such as Transfusion Medicine, Laboratory Testing, and Research. Transfusion Medicine is crucial for ensuring safe blood transfusions, which directly impacts patient outcomes. Meanwhile, Laboratory Testing is vital for disease diagnosis and treatment, highlighting its significant contribution to the healthcare system. The Research aspect fuels innovation and advancements in immunohematology practices, addressing current challenges and improving efficiency. Thus, segments like Transfusion Medicine dominate due to increasing surgical procedures and blood donation activities, while Laboratory Testing maintains a stronghold owing to rising disease prevalence and technology integration. The overall Global Immunohematology Market statistics reveal a robust framework for growth driven by emerging trends alongside market challenges such as regulatory hurdles and competition, creating opportunities for advancements and innovation across these applications. ### **Immunohematology Market End User Insights** The Global Immunohematology Market has shown robust growth across various End User sectors, prominently featuring hospitals, blood banks, and diagnostic laboratories. In 2024, the overall market value is projected to reach 3.36 billion USD, reflecting steady demand for immunohematology tests and services in clinical settings. Hospitals play a crucial role, as they require comprehensive blood typing and cross-matching services for transfusions. Blood banks hold a significant position by ensuring the safe collection, testing, and distribution of blood products, thus affecting a large number of patients.Diagnostic laboratories are integral to this market, given their responsibilities in conducting various immunohematological tests to identify blood group antigens and antibodies. The significant interplay of these End User sectors is driven by increasing healthcare spending and the rising prevalence of blood disorders, bolstering the Global Immunohematology Market revenue substantially. With the anticipated growth in these sectors, backed by advancements in technology and increased awareness of blood transfusion safety, this market segment continues to flourish and adapt to evolving healthcare needs. The interplay of these dynamics positions the Global Immunohematology Market for continued expansion, reflecting positive Global Immunohematology Market Statistics and data trends. ### **Immunohematology Market Test Type Insights** The Global Immunohematology Market, specifically focusing on the Test Type segment, is experiencing significant growth, with an expected valuation of 3.36 billion USD in 2024. This industry is characterized by its diverse range of testing methodologies, which play a vital role in blood transfusions and organ transplants. Among these, Blood Grouping Tests are crucial for ensuring compatibility between donors and recipients, thereby reducing the risk of transfusion reactions. Cross-Matching Tests hold significant importance as they further confirm compatibility, providing an essential safeguard in transfusion procedures. Additionally, Antibody Screening Tests are foundational for identifying potential risks prior to transfusion, enabling healthcare providers to make informed decisions. The interplay of these testing methods is driving the Global Immunohematology Market revenue, contributing to its expanding size and market growth. As the healthcare sector continues to advance, the demand for accurate and reliable immunohematology testing will persist, bolstering the industry’s expansion and influencing Global Immunohematology Market statistics and data. The focus on enhanced patient safety and technological advancements will offer ample opportunities, while potential challenges include regulatory hurdles and the need for skilled personnel in laboratories. ### **Immunohematology Market Regional Insights** The Global Immunohematology Market is projected to experience significant growth across various regions, highlighting diverse trends and opportunities. In 2024, North America leads the Global Immunohematology Market with a valuation of 1.34 USD Billion, driven by advanced healthcare infrastructure and a robust demand for blood transfusion diagnostics. Europe follows with a valuation of 1.05 USD Billion, reflecting a strong emphasis on patient safety and regulatory compliance. The APAC region is valued at 0.8 USD Billion, showcasing a growing market potential fueled by increasing healthcare expenditure and a rising prevalence of blood disorders. South America, valued at 0.1 USD Billion, is gradually expanding, focusing on improving healthcare access. Meanwhile, the MEA region stands at 0.07 USD Billion, with opportunities arising from advancements in medical technology and rising healthcare investments. Among these, North America holds a majority share, signifying its vital role in the Global Immunohematology Market revenue, while regions like APAC present significant growth potential due to emerging healthcare markets. This segmentation reflects a diverse landscape shaped by regional healthcare dynamics and varying market drivers, emphasizing the importance of the Global Immunohematology Market Statistics in understanding the overall industry trajectory. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Immunohematology Market Key Players and Competitive Insights** The Global Immunohematology Market is characterized by a competitive landscape that is continually evolving, driven primarily by advancements in technology, regulatory changes, and rising demand for transfusion medicine. The market comprises a mix of well-established players and emerging companies that are striving to enhance their product offerings and improve patient outcomes. The competitive environment is marked by increased investment in research and development, strategic partnerships, and collaborations aimed at leveraging innovative solutions to meet the complexities of immunohematology testing. Additionally, the growing emphasis on personalized medicine and patient safety has fostered a landscape where the adoption of advanced diagnostic instruments and blood typing procedures is becoming essential. Competition in this sector remains intense, with a push towards both enhancing capabilities and expanding market reach.Abbott Laboratories has maintained a strong position within the Global Immunohematology Market by leveraging its extensive portfolio of innovative diagnostic solutions and a robust distribution network. Their advanced blood screening products are known for enhancing the efficiency and reliability of blood transfusion processes. The company’s strengths lie in its commitment to innovation and quality control, which have established Abbott Laboratories as a trusted name among healthcare providers. Additionally, Abbott's focus on integrating automation and digitization into immunohematology processes has enabled it to enhance operational efficiencies, thereby improving turnaround times for testing and ensuring the safety of blood supplies. This strategic approach, combined with a strong brand reputation, has cemented Abbott Laboratories' competitive edge in the immunohematology arena. Thermo Fisher Scientific has proven to be a formidable player within the Global Immunohematology Market by continually expanding its portfolio and advancing its technological capabilities. The company is recognized for its state-of-the-art products that cater to blood screening and typing needs, which are crucial for effective patient care and safety during transfusions. Thermo Fisher Scientific focuses on delivering high-quality, reliable solutions that help laboratories optimize workflows while maintaining regulatory compliance. Their strengths include a comprehensive range of immunohematology instruments and consumables that are designed to facilitate accurate testing and enhance laboratory productivity. Moreover, Thermo Fisher’s commitment to customer support and training further solidifies its presence in the market, establishing strong relationships with healthcare professionals who rely on their systems to provide safe and efficient patient care. ### **Key Companies in the Immunohematology Market Include** ### Immunohematology Industry Developments - **Q2 2024: Bio-Rad Launches IH-500 Fully Automated Immunohematology System in the U.S.** Bio-Rad Laboratories announced the U.S. launch of its IH-500 system, a fully automated immunohematology analyzer designed to streamline blood typing and antibody screening in clinical laboratories. - **Q2 2024: Grifols Receives FDA Approval for Erytra Eflexis Automated Blood Group Analyzer** Grifols secured FDA clearance for its Erytra Eflexis analyzer, expanding its portfolio of automated immunohematology solutions for blood banks and transfusion centers in the United States. - **Q2 2024: Ortho Clinical Diagnostics Announces Partnership with NHS Blood and Transplant** Ortho Clinical Diagnostics entered a strategic partnership with NHS Blood and Transplant to supply advanced immunohematology testing platforms across the UK’s national blood service. - **Q3 2024: Quotient Limited Appoints New CEO to Drive Immunohematology Product Expansion** Quotient Limited named a new Chief Executive Officer, aiming to accelerate the development and commercialization of its MosaiQ immunohematology platform. - **Q3 2024: Immucor Opens New Manufacturing Facility for Immunohematology Reagents in Georgia** Immucor inaugurated a new production facility in Georgia to increase capacity for its immunohematology reagents, supporting growing demand from hospitals and blood banks. - **Q3 2024: Bio-Rad Laboratories Expands Partnership with Canadian Blood Services** Bio-Rad Laboratories extended its agreement with Canadian Blood Services to provide immunohematology analyzers and reagents for nationwide blood testing operations. - **Q4 2024: Grifols Launches New DG Gel Cards for Advanced Antibody Screening** Grifols introduced its latest DG Gel Cards, designed to enhance antibody detection and compatibility testing in transfusion medicine. - **Q4 2024: Ortho Clinical Diagnostics Wins Major Contract with German Red Cross** Ortho Clinical Diagnostics secured a multi-year contract to supply immunohematology analyzers and consumables to the German Red Cross blood donation centers. - **Q1 2025: Quotient Limited Raises $30 Million in Series C Funding to Advance MosaiQ Platform** Quotient Limited completed a $30 million Series C funding round to support further development and regulatory submissions for its MosaiQ immunohematology system. - **Q1 2025: Bio-Rad Laboratories Receives CE Mark for IH-1000 Immunohematology Analyzer** Bio-Rad Laboratories obtained CE Mark approval for its IH-1000 analyzer, enabling commercial distribution across the European Union. - **Q2 2025: Immucor Announces Strategic Collaboration with Japanese Red Cross Society** Immucor entered a strategic collaboration with the Japanese Red Cross Society to deploy its immunohematology testing solutions in blood centers throughout Japan. - **Q2 2025: Grifols Acquires Stake in Immunohematology Startup for $45 Million** Grifols acquired a minority stake in a U.S.-based immunohematology startup, aiming to accelerate innovation in blood compatibility testing technologies. ## **Immunohematology Market Segmentation Insights** ### **Immunohematology Market** **Product Type** **Outlook** ### **Immunohematology Market** **Application** **Outlook** ### **Immunohematology Market** **End User** **Outlook** ### **Immunohematology Market** **Test Type** **Outlook** ### **Immunohematology Market** **Regional** **Outlook** ## Market Drivers ### Increasing Demand for Automated High-Throughput Testing Systems The growing demand for automated, high-throughput testing systems is creating a transformative opportunity in the Immunohematology Market by addressing the critical need for speed, standardization, and error reduction in large-scale blood processing. As laboratories face increasing test volumes alongside a shortage of skilled personnel, these advanced systems enable the simultaneous processing of hundreds of samples with minimal human intervention.   - PubMed studies indicate automated immunohematology platforms can reduce manual errors by up to 80% while significantly increasing sample processing capacity, strengthening laboratory efficiency and accelerating adoption of high-throughput blood compatibility testing systems globally. ## Future Outlook The Immunohematology Market size is projected to reach USD 2,711.24 Million by 2035, growing at a CAGR of 4.3%, driven by increasing demand for high-performance computing and enhanced security features. **New opportunities:** - Growth of Point-of-Care Testing (POCT). Increasing Demand for Automated High-Throughput Testing Systems. By 2035, the Immunohematology Market is expected to achieve robust growth, reflecting evolving healthcare demands. ## Segment Insights ### By Product: Reagents (largest market) vs instruments / analyzers (fastest growing) Based on products, the Immunohematology Market is segmented into reagents, instruments / analyzers, and consumables & accessories. The Reagents segment dominated the market in 2025 holding market share of 52% , while the Instruments / Analyzers segment is projected to be the fastest-growing segment during the forecast period, 2026–2035. Abbott continues expanding diagnostic reagent portfolios supporting blood screening and immunohematology workflows. Reagent demand remains recurring because every blood compatibility test requires consumable-based processing, reinforcing dominant segment positioning. ### By Application: Blood Related Disorders (largest market) vs HIV (fastest-growing) Based on application, the Immunohematology Market is bifurcated into blood related disorders and HIV. The Blood Related Disorders segment dominated the market in 2025 with market share of 68%, and this segment is projected to be the fastest-growing segment during the forecast period, 2026–2035. Merck KGaA supports hematology diagnostics through specialized life science solutions. Rising prevalence of anemia and hereditary blood disorders increases routine transfusion testing demand, strengthening the segment’s market leadership. ### By End User: hospitals (largest market) vs diagnostic laboratories (fastest-Growing) Based on end user, the Immunohematology Market is segmented into hospitals, diagnostic laboratories, and blood banks. The Hospitals segment dominated the market in 2025 with market share of 57%, while the Diagnostic Laboratories segment is projected to be the fastest-growing segment during the forecast period, 2026–2035. ## Regional Market Share Analysis ### North America**:**Expanding highly developed healthcare system North America leads in the Immunohematology Market Size, accounting for over 85.17% of the global revenue in 2024, driven by a highly developed healthcare system, high blood‑transfusion volumes, and stringent regulatory standards for blood safety. The region has rapid adoption of automated blood‑grouping platforms, molecular diagnostics (PCR, NGS), and integrated digital systems that link blood banks with hospital EMRs and haemovigilance databases. - The U.S. performs approximately 13.6 million whole blood and red blood cell donations annually, supporting sustained demand for immunohematology testing, transfusion safety protocols, and automated compatibility screening systems. Ongoing government initiatives, advanced donor‑management infrastructures, and a strong presence of global vendors such as Grifols, Immucor, Abbott, and Thermo Fisher support continuous modernization of transfusion services and drive steady mid‑single‑digit CAGR growth through 2034. - GE Healthcare continues expanding AI-enabled diagnostic technologies that improve laboratory workflows and support faster interpretation of transfusion-related testing, enhancing blood safety infrastructure across North American healthcare systems. ### Europe: Growing immunohematology market Europe Immunohematology Market size was valued at USD 528.378 million in 2024, making it the second-largest regional market with a 30% share. Europe is a mature but still growing immunohematology market, characterized by centralized national blood services, strong regulatory frameworks under EU directives, and a focus on standardization and haemovigilance. Countries such as Germany, the UK, and France lead adoption, with many transfusion centers operating semi‑automated or fully automated platforms and implementing molecular‑based antigen genotyping for high‑risk patients.  - The European Medicines Agency (EMA) supports advanced therapy and diagnostic evaluation pathways, accelerating adoption of precision diagnostics. Strong regulatory harmonization across Europe supports expansion of standardized immunohematology and blood safety testing systems. Regional growth is supported by ageing populations, rising incidence of hematologic disorders, and investment in digital health, pushing the European segment to expand at a CAGR of roughly 5–8% over the 2024–2031 horizon, depending on the study. ### Asia Pacific: Rising awareness of blood safety Asia Pacific is the fastest‑growing region in immunohematology, driven by improving healthcare infrastructure, rising awareness of blood safety, and government‑led voluntary‑donation campaigns. Countries such as India, China, Japan, and South Korea are expanding their network of accredited blood banks and central transfusion services, while also investing in automation, EQAS‑linked quality programs, and digital donor registries (for example, India’s e‑Rakt Kosh and Rare Donor Registry). The APAC market is expected to grow from around USD 660–700 million in 2024–2025 toward USD 1+ billion by the early 2030s, reflecting strong demand for both reagents and next‑generation testing platform. ### South America: Protection of largely manual tube‑based South America’s immunohematology market is mid‑sized and characterized by gradual modernization of public‑sector transfusion services, especially in countries such as Brazil, Argentina, and Chile. These markets are shifting from largely manual tube‑based methods toward semi‑automated platforms and basic molecular screening, supported by national blood‑safety programs and WHO‑aligned standards. Growth is moderate but persistent, reflecting rising demand for oncology, surgical, and trauma care, as well as government efforts to expand voluntary blood‑donation networks and digital tracking systems. ### Middle East & Africa: Emerging largely manual tube‑based The Middle East and Africa represent a smaller but structurally evolving immunohematology market, with growth concentrated in the Gulf Cooperation Council (GCC) countries and selected higher‑income African nations. These regions are adopting modern blood‑banking practices, including basic automation, improved screening for transfusion‑transmitted infections, and participation in regional haemovigilance and quality‑assurance schemes. However, growth is constrained by uneven healthcare funding, limited skilled workforce, and variable regulatory harmonization, which keeps the MEA segment at a lower share and more volatile growth trajectory compared with North America, Europe, and APA reas. ## Competitive Benchmarking Many global, regional, and local vendors characterize the Immunohematology Market . The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.   The major players in the market Include Thermo Fisher Scientific Inc., Abbott, Merck KGaA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Grifols, S.A., Bio-Rad Laboratories, Danaher Corporation, Cardinal Health, strategic market developments and decisions to improve operational effectiveness. ## Recent News & Developments **January 2026:** Ortho Clinical Diagnostics announced the availability of Immediate Spin Crossmatch (ISXM) on the company’s ORTHO VISION and ORTHO VISION MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions. ISXM is a serological test used in blood transfusions to detect ABO blood type incompatibility between donor red blood cells and recipient serum/plasma. While electronic crossmatch is becoming more prevalent, many laboratories still perform full crossmatches (AHG/IAT). When a full crossmatch is performed, it is required to also complete an ISXM test. **March 2026:** Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID-Cards. In an evolving environment, with the IH-500 NEXT System, Bio-Rad offers enhanced benefits to address the current and future needs of laboratories. **January 2026:** Quidel Corporation and Ortho Clinical Diagnostics Holdings plc announced that they have entered into a definitive agreement in which Quidel acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho’s closing price on December 22, 2021 and an equity value of approximately $6.0 billion. ## Report Scope | Market Application 2024 |   1,761.26 (USD Million) | | --- | --- | | Market Application 2025 | 1,810.36 (USD Million) | | Market Application 2035 | 2,711.24 (USD Million) | | Compound Annual Growth Rate (CAGR) | 4.3% (2025 - 2035) | | Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | Base Year | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific Inc., Abbott, Merck KGaA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Grifols, S.A., Bio-Rad Laboratories, Danaher Corporation, Cardinal Health. | | Segments Covered | By Product By Application By End User | | Key Market Opportunities | Growth of Point-of-Care Testing (POCT) Increasing Demand for Automated High-Throughput Testing Systems. | | Key Market Dynamics | Rising Prevalence of Blood Disorders and Chronic Diseases Automation and technological advancement Increasing Blood Donations and Transfusion Procedures. | | Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. | ## Frequently Asked Questions **Q: How much is the Immunohematology Market?** A: USD 2,711.24 Million (2035) is the Immunohematology Market **Q: What is the growth rate of the Immunohematology Market?** A: 4.3% is the growth rate of the Immunohematology Market **Q: Which region held the largest market share in the Immunohematology Market?** A: North America held the largest market share in the Immunohematology Market. **Q: Who are the key players in the Immunohematology Market?** A: Bayer AG, Merck KGaA, Pfizer Inc., Reckitt Benckiser, Church & Dwight Co., Inc., AbbVie Inc., Organon & Co., Merck & Co., Ferring Pharmaceuticals, Amgen Inc are the key players in the Immunohematology Market. **Q: Which End User had the largest market share in the Immunohematology Market?** A: Hospitals had the largest market share in the Immunohematology Market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immunohematology-market-42784*